ot love occupational therapy p.c.

1 maiden lane 5th floor
new york, new york 10038

NYS Entity Status
ACTIVE

NYS Filing Date
APRIL 15, 2014

NYS DOS ID#
4561791

County
SUFFOLK

Jurisdiction
NEW YORK

Registered Agent
SPIEGEL & UTRERA P.A. P.C.
1 MAIDEN LANE 5TH FLOOR
NEW YORK, NEW YORK, 10038

NYS Entity Type
DOMESTIC PROFESSIONAL CORPORATION

Name History
2014 - OT LOVE OCCUPATIONAL THERAPY P.C.









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy New York
  • Hiring a shrink could make your company more successful
    By Moneyish - Monday Sep 4, 2017

    This isn’t the kind of occupational therapy you’re used to. When Jonathan Pellegrin, the former chairman and CEO of publishing company Johnson Hill Press and author of “The Art of Selling the Family Business,” saw trouble brewing at his company, he knew just where to turn: a therapist specializing in workplace issues. With a history...

    Source: New York Post: Business
  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York
  • Acorda Scraps One Parkinson’s Drug, Puts Its Cash Behind Another
    By Frank Vinluan - Monday Nov 20, 2017

    Acorda Therapeutics said Monday that it will stop work on an experimental treatment for Parkinson’s disease, spelling the end for a drug the Ardsley, NY, company added to its pipeline last year in a $363 million deal. The announcement follows the recent emergence of safety problems for the Acorda (NASDAQ: ACOR) drug, tozadenant. Acorda said […]

    Source: Xconomy New York
  • The Neediest Cases Fund: ‘Coming Out of a Cloud’ After Drug Abuse and Mental Illness
    By EMILY PALMER - Wednesday Oct 25, 2017

    Wanda Ramirez, who has schizophrenia, used to smoke marijuana to get her through the day. In treatment, her love of drawing was fostered through art therapy.

    Source: NYT > Home Page